1 | Belantamab mafodotin | 1件: Belantamab mafodotin Belantamab mafodotin (Belantamab mafodotin) | 1件: Belantamab mafodotin
Belantamab mafodotin
(Belantamab mafodotin, Belantamab mafodotin, Belantamab mafodotin-blmf) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬
| 13件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Motor proteins, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|
2 | Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks AS determined BY part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin (Belantamab mafodotin) | 1件: Belantamab mafodotin
Belantamab mafodotin
(Belantamab mafodotin, Belantamab mafodotin, Belantamab mafodotin-blmf) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB, TUBB 💬
| 13件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Motor proteins, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|